Roivant Sciences

Contributing Author

Recent Articles by Roivant Sciences

Nov-10	Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology ROIV GlobeNewswire
Nov-09	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update ROIV GlobeNewswire
Oct-29	Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift ROIV GlobeNewswire
Oct-21	Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) ROIV +5.38% GlobeNewswire
Oct-21	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 ROIV +5.38% GlobeNewswire
Sep-23	Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus ROIV GlobeNewswire
Sep-08	Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study ROIV +18.75% GlobeNewswire
Sep-06	Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call ROIV GlobeNewswire
Aug-27	Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. ROIV ROIV -7.64% GlobeNewswire
Aug-27	Priovant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. ROIV ROIV -7.64% GlobeNewswire
Aug-26	JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Aug-06	Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) ROIV GlobeNewswire
Aug-06	Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update ROIV GlobeNewswire
Jul-23	Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 ROIV GlobeNewswire
May-20	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update ROIV +14.89% GlobeNewswire
May-11	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 ROIV GlobeNewswire
Apr-02	Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) ROIV GlobeNewswire
Apr-02	Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) ROIV GlobeNewswire
Mar-28	New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Mar-03	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna ROIV ROIV +6.00% GlobeNewswire
Mar-03	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Feb-06	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) ROIV +22.14% GlobeNewswire
Feb-06	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 ROIV +22.14% GlobeNewswire
Jan-23	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 ROIV GlobeNewswire
Dec-11	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day ROIV +5.43% GlobeNewswire
Nov-10	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update ROIV GlobeNewswire
Oct-27	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 ROIV GlobeNewswire
Sep-17	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) ROIV +7.76% GlobeNewswire
Sep-11	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List ROIV GlobeNewswire
Sep-03	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients ROIV GlobeNewswire
Aug-11	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update ROIV GlobeNewswire
Jul-28	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 ROIV GlobeNewswire
Jun-09	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis ROIV GlobeNewswire
May-29	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update ROIV +6.40% GlobeNewswire
May-15	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 ROIV GlobeNewswire

Roivant Sciences

Recent Articles by Roivant Sciences

Upgrade your Finviz experience